Skip To Main Content
Gaelen Snell on Muck Rack

Gaelen Snell

As seen in: The Lancet

Get in touch with Gaelen

Contact Gaelen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study

|
By Gaelen Snell, Alison D. Marshall, Jennifer van Gennip, Matthew Bonn
| canlivj.utpjournals.press
Canada has committed to eliminating viral hepatitis as a major public health threat by 2030, setting benchmarks to reduce new hepatitis C virus (HCV) cases by 90% and ensure that 80% of eligible people receive treatment (1). Direct-acting antiviral (DAA) therapies cure greater than 90% of cases, and without a vaccine against HCV, are key to achieving elimination targets (2–4). As such, DAA access is essential to deliver on Canada’s commitment to HCV elimination.
Open in Who Shared Issue with article?
See all 1 articles